Navigation Links
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Date:9/24/2008

e (SAD) Study in Healthy Volunteers (Poster #1871): ITMN-191 was safe and well tolerated when given as a single dose to healthy adults in a range of doses from 2mg to 1600mg. Adverse events were generally mild and transient and were similar between treatment groups, with the exception of a higher frequency of mild and transient diarrhea and abdominal pain in the ITMN-191 group at the highest tested dose (1600mg). The pharmacokinetics of ITMN-191 were linear over the dose range of 100mg to 800mg. Co-administration of ITMN-191 with food increased the expected trough and AUC by 40-50% compared with administration of ITMN-191 without food. This "food effect" enabled InterMune and Roche to explore a lower range of doses of ITMN-191 in subsequent clinical studies than was previously planned.

-- A Phase 1b Monotherapy Multiple-Ascending-Dose (MAD) Study in HCV Genotype 1 Patients (Poster #1847): ITMN-191 was administered as mono-therapy for 14 days to four cohorts of treatment-naive patients infected with HCV genotype 1. Multiple ascending doses were examined up to a total daily dose of 600mg. The safety and tolerability of ITMN-191 were excellent. Adverse events were generally mild and transient, with no evidence of clinically significant laboratory abnormalities or ECG changes. When ITMN-191 was administered every eight or twelve hours, viral kinetic results were very competitive with those of other direct antiviral compounds studied in similar experiments.

The MAD study also included one exploratory cohort of ITMN-191 given as mono-therapy for 14 days to strictly defined non-responders: HCV genotype 1 patients who had failed to achieve a 2.0 log10 reduction in HCV RNA with prior standard-of-care treatment, or who still had detectable HCV RNA after 24 weeks of treatment. At the one dose studied of 300mg given every 12 hours, ITMN-191 delivered a median reduction of HCV RNA at study day 14 of 2.5 log10. The results from this initial exploratory cohort in non
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
4. InterMune to Present at BMO Healthcare Conference
5. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6. InterMune to Present at Jefferies Healthcare Conference
7. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
8. InterMune to Present at Citigroup Healthcare Conference
9. InterMune to Present at Bank of America Health Care Conference
10. InterMune to Present at Deutsche Bank Health Care Conference
11. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply ... risk management and resiliency practitioners with luminaries and thought leaders to advance the ... recognized for their innovations and performance excellence. At that time its principle sponsor, ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with ... brighten their day. The biotechnology company, located in the ... one of the best potential therapies yet for people ... entitled, " Correction of Down syndrome and Edwards syndrome ... journal DNA Research . Elixirgen plans to develop ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... Inc.,(Nasdaq: RDEA ) announced today that Barry D. Quart, PharmD, ... UBS Global Life Sciences Conference, Date: ... Time Location: Grand Hyatt, New York ... Focus Conference, Date: Tuesday, October 7, 2008 ...
... Serve Growing Highly-Potent and Cytotoxic ... ... Pharmatek -- a,pharmaceutical chemistry development organization supporting the,pharmaceutical industry -- ... in San Diego., The 18,000 sq. ft. facility includes ...
... the use of sensors or barcodes at the nanoscale, North ... tiny organic particles, when heated to the proper temperature, bob ... film and then can reversibly recede below the surface when ... of particles to a surface and then sinking them back ...
Cached Biology Technology:Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference 2Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2NC State engineers discover nanoparticles can break on through 2
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/31/2015)... 31, 2015 Growing need for ... government digitization projects to drive India ... TechSci Research report, " India Biometrics Market Forecast & Opportunities, ... is projected to grow at a CAGR of over 35% ... on account of extensive use of biometric technology in the ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced the ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.23 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
... 03, 2010, Seoul, S. Korea Institut Pasteur Korea ... the chemical compound collection of Novartis Institute for Tropical ... IP-K,s PhenomicScreen is a high-throughput, high-content visual screening ... Over the past year, PhenomicScreen has been used to ...
... Intense, individually tailored dietary treatment for acutely hospitalized elderly ... new study by researchers at Ben-Gurion University of the ... prestigious Journal of the American Geriatric Society ... percent) of the control group compared to the intervention ...
... Several of the most promising technological research projects at ... infusion of federal cash to help them through the ... the commercial market. With $5.1 million in federal ... System of Maryland research institutions and the U.S. Army ...
Cached Biology News:Personalized diets for elderly after hospitalization decreases mortality rates 2$5.1 million Army-Md. alliance speeds university research to market 2$5.1 million Army-Md. alliance speeds university research to market 3$5.1 million Army-Md. alliance speeds university research to market 4$5.1 million Army-Md. alliance speeds university research to market 5
... Genetic Analysis System, which processes two 96-well plates ... adds a higher level of throughput to the ... of Beckman Coulters new GenomeLab family of products*, ... Biomek series liquid handers, for increased automation. ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Pathway Studio Enterprise is integrated informatics ... regulatory mechanisms and drug response modeling. ... the worlds largest knowledge base of ... with MedScan module capable of extracting ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
Biology Products: